CLASS III Drug recall · Reported 13 Sep 2023 · FDA Enforcement Report
Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg recalled by Esperion
Esperion is recalling Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, distributed nationwide in the US. The recall was initiated on 16 Aug 2023 and the FDA has classified it as Class III.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-1143-2023
- FDA event ID
- 92897
- Recalling firm
- Esperion, Ann Arbor, MI
- Brand
- Nexlizet
- Manufacturer
- Esperion Therapeutics, Inc.
- Classification
- Class III
- Status
- Terminated
- Recall initiated
- 16 Aug 2023
- FDA classified
- 6 Sep 2023
- Reported
- 13 Sep 2023
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Potency & Assay
- Drug class
- Cholesterol Medication
Timeline
| 16 Aug 2023 | Recall initiated by company | |
| 6 Sep 2023 | Classified by FDA | +21 days |
| 13 Sep 2023 | Published in enforcement report | +7 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Failed dissolution specifications: below specification results at stability 12-month
Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.
Product as listed by the FDA
Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03
Where it was distributed
Nationwide USA
Questions about this recall
Why was it recalled?
Failed dissolution specifications: below specification results at stability 12-month
Which lots are affected?
Lot# 1904872, Exp 1/31/2025; 1950377, Exp 6/30/2025
Where was it sold?
Nationwide USA
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class III mean?
Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
More recalls from Esperion
All 2| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Nexlizet (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg recalledNexlizet | Esperion | Potency & Assay | Nationwide |
Other Bempedoic Acid recalls
All 2| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Nexlizet (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg recalledNexlizet | Esperion | Potency & Assay | Nationwide |